Enhancing [ 177 Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics

Background: Peptide receptor radionuclide therapy (PRRT) uses [177Lu]Lu-[DOTA0-Tyr3]octreotate ([177Lu]Lu-DOTA-TATE) to treat patients with neuroendocrine tumours (NETs) overexpressing the somatostatin receptor 2A (SSTR2A). It has shown significant short-term improvements in survival and symptom all...

Descrizione completa

Dettagli Bibliografici
Autori principali: Cheng, J, Zink, J, O’Neill, E, Cornelissen, B, Nonnekens, J, Livieratos, L, Terry, SYA
Natura: Journal article
Lingua:English
Pubblicazione: SpringerOpen 2024

Documenti analoghi